# Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

> **NCT05577754** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 20 (estimated)

## Conditions studied

- Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

## Interventions

- **DRUG:** Alpelisib (BYL719)
- **DRUG:** Matching placebo
- **PROCEDURE:** Optional lumbar puncture + blood sample

## Key facts

- **NCT ID:** NCT05577754
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-28
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577754, "Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05577754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*